Calcified Tissue International

, Volume 35, Issue 1, pp 376–382 | Cite as

Sequential changes in mineral metabolism and serum vitamin D metabolite concentrations produced by phenobarbital administration in the rat

  • Theodore J. Hahn
  • Linda R. Halstead
Laboratory Investigations

Summary

We examined the effect of daily phenobarbital administration on serum vitamin D metabolite levels and indices of vitamin D biologic activity in 7-week-old male rats maintained on parenteral vitamin D supplementation (125 ng/day). Treatment with phenobarbital (75 mg/kg/day) produced a biphasic response in parameters of vitamin D biologic effect, including serum calcium concentration, serum inorganic phosphate concentration, and intestinal45Ca calcium absorption. An initial increase in these values, maximal after 3–5 days of treatment, was followed by a subsequent decline to subnormal levels by day 21. A parallel biphasic pattern was observed for serum 25-hydroxyvitamin D (25OHD) concentration. Serum 25OHD reached a peak increase of 87% above control levels (P<0.01), observed after 5 days of treatment, and subsequently declined to 62% of control animal values (P<0.01) by 21 days. Serum 24,25(OH)2D concentration followed a similar course and exhibited a strong positive correlation with serum 25OHD concentrations (r=0.74,P<0.01). In contrast, serum 1,25(OH)2D concentration was not significantly different from control values after 5 days but was increased 80% over control values (P<0.05) by day 21. Serum vitamin D concentration declined progressively in treated animals, falling to 50% of control levels (P<0.05) by day 5 and to 27% of control levels (P<0.001) by day 21. At the point of maximal increase in serum 25OHD concentration, hepatic microsomal vitamin D3-25-hydroxylase activity was not increased in the treated animals whereas hepatic mitochondrial vitamin D3-25-hydroxylase activity was increased by 2.4-fold. Increased hepatic mitochondrial vitamin D3-25-hydroxylase activity persisted through 21 days of phenobarbital treatment. It is concluded that phenobarbital administration in the rat produces an initial increase in vitamin D biologic effect which correlates temporally with increased circulating levels of 25OHD, the latter possibly resulting from increased hepatic mitochondrial vitamin D-25-hydroxylase activity. A subsequent decline in serum 250HD concentration may be the result of decreased availability of vitamin D as substrate. This sequence of alterations in vitamin D metabolism bears potentially important implications for the timing of prophylactic vitamin D supplementation in patients treated with anticonvulsant drugs.

Key words

25-hydroxyvitamin D Phenobarbital Vitamin D biologic activity Drug-induced bone mineral disorders 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Richens A, Rowe DJF (1970) Disturbance of calcium metabolism by anticonvulsant drugs. Brit J Med 3:73–76Google Scholar
  2. 2.
    Dent DE, Richens A, Rowe DJF, Stamp TCB (1970) Osteomalacia with long-term anticonvulsant therapy in epilepsy. Brit Med J 4:69–72PubMedGoogle Scholar
  3. 3.
    Hahn TJ, Hendin BA, Scharp CR, Haddad Jr JG (1972) Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 287:900–904PubMedCrossRefGoogle Scholar
  4. 4.
    Hahn TJ, Hendin BA, Scharp CR, Boisseau VC, Haddad Jr JG (1975) Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy. N Engl J Med 292:550–554CrossRefGoogle Scholar
  5. 5.
    Tolman KG, Jubiz W, Sannella JJ, Madsen JA (1975) Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children. Pediatrics 56:45–51PubMedGoogle Scholar
  6. 6.
    Bouillon R, Reynaut J, Claes JG, Lissens W, DeMoor P (1975) The effect of anticonvulsant therapy on serum levels of 25-hydroxyvitamin D calcium and parathyroid hormone. J Clin Endocrinol Metab 41:1130–1136PubMedGoogle Scholar
  7. 7.
    Mosekilde L, Christensen MS, Lund B, Sorensen OH, Melsen F (1975) The interrelationships between serum 25-hydroxycholecalciferol, serum parathyroid hormone and bone changes in anticonvulsant osteomalacia. Acta Endocrinol (Copenh) 84:559–565Google Scholar
  8. 8.
    Jubiz W, Haussler MR, McCain TA, Tolman K (1977) Plasma 1,25-dihydroxy-vitamin D levels in patients receiving anticonvulsant drugs. J Clin Endocrinol Metab 44:617–621PubMedGoogle Scholar
  9. 9.
    Hahn TJ, Halstead LR (1979) Anticonvulsant drug-induced osteomalacia: alterations in mineral metabolism and response to vitamin D3 administration. Calcif Tissue Int 27:13–18PubMedGoogle Scholar
  10. 10.
    Gascon-Barre M, Cote MG (1978) Influence of phenobarbital and diphenylhydantoin on the healing of rickets in the rat. Calcif Tissue Res 25:93–97CrossRefPubMedGoogle Scholar
  11. 11.
    Harris M, Rowe DJF, Darby AJ (1978) Anticonvulsant osteomalacia induced in the rat by diphenylhydantoin. Calcif Tissue Res 25:13–17CrossRefPubMedGoogle Scholar
  12. 12.
    Villareale M, Gould LV, Chisoff RT, Bergstrom WH (1974) Diphenylhydantoin: effects on calcium metabolism in chickens. Science 183:671–673PubMedGoogle Scholar
  13. 13.
    Norman AW, Bayless JD, Tsai HC (1976) Biologic effects of short-term phenobarbital treatment on the response to vitamin D and its metabolites in the chick. Biochem Pharmacol 25:163–175CrossRefPubMedGoogle Scholar
  14. 14.
    Stamp TCB, Round JM, Rowe DJF, Haddad JG (1972) Plasma levels and therapeutic effect of 25-hydroxycholecalciferol in epileptic patients taking anticonvulsant drugs. Brit Med J 4:9–12PubMedCrossRefGoogle Scholar
  15. 15.
    Maclaren NK, Lipshitz F (1973) Vitamin D dependency rickets in institutionalized, mentally retarded children on long-term anticonvulsant therapy. II. The response to 25-hydroxycholecalciferol and vitamin D. Pediatr Res 7:914–923PubMedCrossRefGoogle Scholar
  16. 16.
    Hahn TJ, Birge SJ, Scharp CR, Avioli LV (1972) Phenobarbital-induced alterations in vitamin D metabolism. J Clin Invest 51:741–748PubMedGoogle Scholar
  17. 17.
    Silver J, Neale G, Thompson GR (1974) Effect of phenobarbitone treatment on vitamin D metabolism in mammals. Clin Sci Mol Med 46:433–448PubMedGoogle Scholar
  18. 18.
    Rudra MN, De S, Rudra MS (1969) Calcium metabolism in epilepsy. N Engl J Med 28:1242–1243Google Scholar
  19. 19.
    Dymling JF, Lidgren L, Walloe A (1979) Biochemical variables related to calcium metabolism in epileptics. Acta Med Scand 205:401–404PubMedCrossRefGoogle Scholar
  20. 20.
    Kepner BL, Hercules DM (1963) Determination of calcium in biologic fluids by fluorescence techniques. Anal Chem 35:1238–1240CrossRefGoogle Scholar
  21. 21.
    Chen TS, Toribara TY, Warnes W (1956) Microdetermination of phosphorus. Anal Chem 28:1756–1758CrossRefGoogle Scholar
  22. 22.
    Shepard RM, Horst RL, Hamstra AJ, DeLuca HF (1979) Determination of vitamin D and its metabolites in plasma from normal and anephric man. Biochem J 182:55–69PubMedGoogle Scholar
  23. 23.
    Hahn TJ, Halstead LR, Baran DT (1981) Effects of short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab 52:111–115PubMedGoogle Scholar
  24. 24.
    Horst RL (1979) 25-OHD3-26,23-lactone: a metabolite of vitamin D3 that is 5 times more potent than 25-OHD3 in the rat plasma competitive protein binding radioassay. Biochem Biophys Res Com 89:286–293PubMedCrossRefGoogle Scholar
  25. 25.
    Coates MD, Holdsworth ES (1961) Vitamin D3 and absorption of calcium in chick. Brit J Nutr 15:131–147CrossRefPubMedGoogle Scholar
  26. 26.
    Hahn TJ, Scharp CR, Avioli LV (1974) Effect of phenobarbital administration on the subcellular distribution of vitamin D3-3H in rat liver. Endocrinology 94:1489–1495PubMedGoogle Scholar
  27. 27.
    Lowry OH, Rosebrough NJ, Farr AL, Randall GA (1951) Protein measurement with Folin phenol reagent. J Biochem 193:265–275Google Scholar
  28. 28.
    Bjorkhem I, Holmberg I (1978) Assay and properties of a mitochondrial 25-hydroxylase active on vitamin D3. J Biol Chem 253:842–847PubMedGoogle Scholar
  29. 29.
    Conney AH, Davison C, Gastel R, Beuns JJ (1960) Adaptive increases in drug-metabolizing enzymes produced by phenobarbital and other drugs. J Pharmacol Exp Ther 130:1–8PubMedGoogle Scholar
  30. 30.
    Haddad JG Jr, Min C, Mendelsohn M, Slatapolsky E, Hahn TJ (1977) Competitive protein-binding radioassay of 24,25-dihydroxyvitamin D in sera from normal and anephric subjects. Arch Biochem Biophys 182:390–395CrossRefPubMedGoogle Scholar
  31. 31.
    Taylor CM, Mawer EB, Wallace JE, St. John J, Cochran M, Russell RBG, Kanis JA (1978) The absence of 24,25-dihydroxycholecalciferol in anephric patients. Clin Sci Mol Med 53:541–549Google Scholar
  32. 32.
    DeLuca, HF (1976) Recent advances in our understanding of the vitamin D endocrine system. J Lab Clin Med 87:7–26Google Scholar
  33. 32.
    Harrison HC, Harrison HE (1976) Inhibition of vitamin D-stimulated active transport of calcium of rat intestine by diphenylhydantoin-phenobarbital treatment. Proc Soc Exp Biol Med 153:220–224PubMedGoogle Scholar
  34. 34.
    Shepard RM, DeLuca HF (1980) Plasma concentrations of vitamin D3 and its metabolites in the rat as influenced by vitamin D3 or 25-hydroxyvitamin D3 intakes. Arch Biochem Biophys 202:43–53CrossRefGoogle Scholar
  35. 35.
    Levinson JC, Kent GN, Worth GK, Retallack RW (1977) Anticonvulsant induced increase in 25-hydroxyvitamin D3-1-α-hydroxylase. Endocrinology 101:1898–1901CrossRefGoogle Scholar
  36. 36.
    Baran DT, Fausto AC, Roberts ML, Karl I, Avioli LV (1979) Phenobarbital-induced alterations in the metabolism of [3H] vitamin D3 by the perfused rachitic rat liver in vitro. J Clin Invest 64:1112–1117PubMedCrossRefGoogle Scholar
  37. 37.
    Cinti DL, Golub EE, Bronner F (1976) 25-hydroxycholecalciferol: high affinity substrate for hepatic cytochrome P-450. Biochem Biophys Res Commun 72:546–553CrossRefPubMedGoogle Scholar
  38. 38.
    Sumi K, Sugita T, Shimotsuji T, Seino Y, Mimaki T, Yabuuchi H (1978) Effect of anticonvulsant therapy on serum 25-hydroxyvitamin D level. Tohoku J Exp Med 125:265–269PubMedCrossRefGoogle Scholar
  39. 39.
    Hahn TJ, (1980) Drug-induced disorders of vitamin D and mineral metabolism. Clin Endocrinol Metab 9:107–129CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1983

Authors and Affiliations

  • Theodore J. Hahn
    • 1
  • Linda R. Halstead
    • 1
  1. 1.Division of Bone and Mineral Metabolism, Department of MedicineWashington University School of Medicine, The Jewish Hospital of St. LouisSt. LouisUSA

Personalised recommendations